The FDA’s latest label change for voclosporin adds data demonstrating its safety and efficacy, as well as a sustained renal response, in patients with lupus nephritis through three years of treatment.
![](https://www.the-rheumatologist.org/wp-content/uploads/2015/05/Drugs_500x270-150x150.gif)
Watch this space for our coverage of systemic lupus erythematosus (SLE) sessions at ACR Convergence 2020, beginning with a report on the State of the Art: Lupus—the Future Is Now session, moderated by Saira Sheikh, MD. Plus, explore our collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of SLE.
The FDA’s latest label change for voclosporin adds data demonstrating its safety and efficacy, as well as a sustained renal response, in patients with lupus nephritis through three years of treatment.
Mery Deeb, MD, Taro Minami, MD, Michael Stanchina, MD, Elias Jabbour, MD, & Jan Karczewski, MD |
Shrinking lung syndrome (SLS) is a rare cause of dyspnea that has been most commonly described in patients with systemic lupus erythematosus (SLE), but is also found in systemic sclerosis, Sjögren’s disease and rheumatoid arthritis. Shrinking lung syndrome is characterized by a restrictive pattern on lung spirometry, despite normal lung parenchyma, and an elevated diaphragm.1…
Chimeric antigen receptor (CAR) T cell therapy has the potential to fundamentally shift the treatment of autoimmune disease. During his presentation at EULAR 2024, Georg Schett, MD, provided an overview of this treatment process and described the promising findings of the latest research.
Aryan Gopinath & Srilatha Kothandaraman, MD |
A school science project demonstrates that flipbooks can be a useful educational tool for patients and their families to learn about rheumatic conditions and their treatment.
SAN DIEGO—As part of a Nov. 14 session on lupus nephritis at ACR Convergence 2023, Simone Appenzeller, MD, PhD, shared perspectives on the importance of biopsy to inform its diagnosis, prognosis and treatment, with an emphasis on childhood disease. Prompt diagnosis and treatment of lupus nephritis is perhaps even more important for children than for…
Vineetha Philip, MD, MPH, Myriam Guevara, MD, Angelina Edwards, MD, & Ziad M. El-Zaatari, MD |
Kidney involvement is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Collectively termed lupus nephritis, SLE with kidney involvement comes in many subtypes. The current classification by the International Society of Nephrology/Renal Pathology Society (ISN/RPS), however, does not include lupus podocytopathy, which, through various clinical and epidemiologic studies, has recently been…
Bryn Nelson, Ph |
In 2022, an international group of researchers reported the seminal finding that a gain-of-function variant of a single-stranded ribonucleic acid (RNA) sensor, known as toll-like receptor 7 (TLR7), can cause human systemic lupus erythematosus (SLE).1 The paper in Nature showed that a newly described variant of TLR7, identified in a child with severe lupus, was…
Yu (Ray) Zuo, MD, MS, & Jason S. Knight, MD, PhD |
Antiphospholipid syndrome (APS) is an acquired thromboinflammatory disease that can have severe, sometimes catastrophic, effects on patients and their families. Our modern understanding of APS began to emerge in the early 1980s. At that point, it was defined as a condition characterized by thrombotic episodes and/or pregnancy complications in the presence of antiphospholipid antibodies (aPL).1…
The FDA has approved tocilizumab-aazg (Tyenne), the first tocilizumab biosimilar, for treating rheumatic diseases, as well as the new drug application for CB-101, a chimeric antigen receptor T cell therapy, for treating lupus nephritis and extra-renal lupus.
Katie Robinson |
Current knowledge of receptor-ligand interactions, cell signaling, and transcriptional regulation derive from studies of type I interferon. The design of novel therapeutics is informed by the advances in investigation of type I interferon, with the potential for important impacts on patient management.